Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab subcutaneous - Roche

Next Previous
Drug Profile

Trastuzumab subcutaneous - Roche

Alternative Names: Herceptin Hylecta; Herceptin SC; Hyaluronidase-trastuzumab; Reformulated Herceptin - Roche; RG597 (SC formulation) - Roche; Trastuzumab SC; Trastuzumab-hyaluronidase

Latest Information Update: 05 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HER2 positive breast cancer
  • No development reported Breast cancer

Most Recent Events

  • 28 Jul 2022 Trastuzumab subcutaneous is still in phase III trials for Breast cancer (Early-stage disease) in Slovenia, Slovakia, Lithuania, Romania, France, Czech Republic, Bulgaria (SC)
  • 10 May 2022 Launched for Her2 positive Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in Italy (SC)
  • 10 May 2022 Launched for Her2 positive Breast cancer (Early-stage disease) in Italy (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top